Peptides for Weight Loss Research GLP-1 Class · Dual/Triple Agonists · Metabolic Pathway Research · ≥99% HPLC · Janoshik COA
GLP-1 receptor agonists represent the most active area of weight loss peptide research in 2025-2026. From first-generation GLP-1R monoagonists (Semaglutide, −14.9% STEP 1) through dual agonists (Tirzepatide, −20.9% SURMOUNT-1) to triple agonists (Retatrutide, −24.2% Phase 2), QSC stocks the complete research series. Also includes amylin pathway research (Cagrilintide), oral GLP-1 analogs (Orforglipron), and GCGR pathway compounds (Survodutide, Eloralintide). All at ≥99% HPLC with Janoshik independent COA.
Weight loss peptide research centers on GLP-1 receptor agonists (Semaglutide, Tirzepatide, Retatrutide), amylin pathway compounds (Cagrilintide), GLP-1/GCGR dual agonists (Eloralintide, Survodutide), oral GLP-1 analogs (Orforglipron), and metabolic compounds (MOTS-c). QSC stocks the complete catalog at ≥99% HPLC with Janoshik COA. Research use only.
What is the most effective GLP-1 peptide in research?
In Phase 2/3 clinical data, Retatrutide (triple GLP-1R/GIPR/GCGR agonist) showed the highest weight reduction at −24.2% in Phase 2 trials — the highest efficacy recorded in trial history to date. Tirzepatide showed −20.9% (SURMOUNT-1) and Semaglutide −14.9% (STEP 1). QSC stocks all three for in vitro research.
What is Retatrutide?
Retatrutide is a triple receptor agonist targeting GLP-1R, GIPR, and GCGR simultaneously. Phase 2 data showed −24.2% weight reduction — the highest efficacy of any compound in this class to date. QSC is one of the few suppliers to stock Retatrutide for research at ≥99% HPLC with Janoshik independent COA. Research use only.
What is Eloralintide?
Eloralintide (MEDI0382) is a dual GLP-1R/GCGR agonist studied in Phase 2 NASH trials, demonstrating approximately 40-50% liver fat reduction. It represents an emerging research direction targeting both weight loss and non-alcoholic steatohepatitis simultaneously. QSC stocks Eloralintide for research. Research use only.
Where can I buy GLP-1 research peptides with Janoshik COA?
QSC supplies the complete GLP-1 research series — Semaglutide, Tirzepatide, Retatrutide, Cagrilintide, Eloralintide, Orforglipron, Survodutide — at ≥99% HPLC with Janoshik independent COA. Publicly verifiable at verify.janoshik.com. Research use only.
Research Use Only: All QSC products sold strictly for in vitro laboratory research. Not for human or veterinary use. Information on this page is educational only and does not constitute medical advice.
